Bonnie is a Venture Partner at Bioqube Ventures in a dual investing and operating role. She is a healthcare venture capitalist and PhD immunologist trained at Oxford, with 9 years of VC experience across Europe and the US.
Prior to Bioqube, Bonnie spent five years at Monograph Capital, a global healthcare VC firm she joined at its founding, covering the full investment cycle. She led Monograph’s participation in MiroBio’s $97M Series B (acquired by Gilead for ~$405M three months later) and sourced its $100M Series C in Autobahn Therapeutics, where she served on the Board and Audit Committee. She also co-founded Ollin Biosciences in 2023.
Before Monograph, Bonnie spent four years at Forbion, involved in eight new biopharma investments including Inflazome (acquired by Roche for ~€1.2B) and Mestag Therapeutics (option-to-acquire deal with Merck worth up to $1.9B). She also built Forbion’s ESG and therapeutic-impact framework.
Bonnie holds a PhD in Immunology from Oxford (Marie-Curie Postdoctoral Fellow) and a BA&Sc from Utrecht University (summa cum laude), with 18 peer-reviewed publications. She co-founded VC Life and YVC Collective, serves on the Board of the largest patient organization supporting people affected by facial pain and is an elite endurance athlete for the Netherlands and Great Britain.
In her free time, Bonnie is an elite endurance athlete for the Netherlands and Great Britain.